We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

29 hedge funds and large institutions have $379K invested in Navidea Biopharmaceuticals Inc. in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

7% more funds holding

Funds holding: 27 → 29 (+2)

3% less capital invested

Capital invested by funds: $392K → $379K (-$13K)

70% less call options, than puts

Call options by funds: $14K | Put options by funds: $47K

Holders
29
Holders Change
+2
Holders Change %
+7.41%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
4
Closed
4
Calls
$14K
Puts
$47K
Net Calls
-$33K
Net Calls Change
-$19K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$16.3K
2
Group One Trading
Group One Trading
Illinois
+$11.9K
3
Citadel Advisors
Citadel Advisors
Florida
+$7.47K
4
ARTA
A.R.T. Advisors
New York
+$6.32K
5
UBS Group
UBS Group
Switzerland
+$2.81K

Top Sellers

Rank Fund Capital Flow
1
WS
Wedbush Securities
California
-$56K
2
VF
Virtu Financial
New York
-$28.1K
3
Jane Street
Jane Street
New York
-$12K
4
ACM
Allred Capital Management
Texas
-$4.98K
5
Citigroup
Citigroup
New York
-$78
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$143K +$16.3K +26,449 +15%
BlackRock
2
BlackRock
New York
$87K +$254 +413 +0.3%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$24K – – –
Citadel Advisors
4
Citadel Advisors
Florida
$20K +$7.47K +12,146 +72%
Group One Trading
5
Group One Trading
Illinois
$16K +$11.9K +19,403 +498%
VF
6
Virtu Financial
New York
$13K -$28.1K -45,747 -71%
California Public Employees Retirement System
7
California Public Employees Retirement System
California
$13K – – –
HighTower Advisors
8
HighTower Advisors
Illinois
$11K -$32 -52 -0.4%
ACM
9
Allred Capital Management
Texas
$8K -$4.98K -8,100 -42%
Northern Trust
10
Northern Trust
Illinois
$8K – – –
ARTA
11
A.R.T. Advisors
New York
$7K +$6.32K +10,276 New
Morgan Stanley
12
Morgan Stanley
New York
$5K – – –
PFO
13
Pathstone Family Office
New Jersey
$5K – – –
Wells Fargo
14
Wells Fargo
California
$5K +$615 +1,000 +15%
UBS Group
15
UBS Group
Switzerland
$3K +$2.81K +4,576 +4,358%
Bank of America
16
Bank of America
North Carolina
$2K +$1.02K +1,656 +130%
SFS
17
Sowell Financial Services
Arkansas
$2K +$1.73K +2,819 New
Victory Capital Management
18
Victory Capital Management
Texas
$2K +$1.75K +2,849 New
Citigroup
19
Citigroup
New York
$1K -$78 -127 -6%
JCM
20
Jacobi Capital Management
Pennsylvania
$1K – – –
JP Morgan Chase
21
JP Morgan Chase
New York
$1K – – –
LFG
22
LifePlan Financial Group
Ohio
$1K – – –
Simplex Trading
23
Simplex Trading
Illinois
$1K +$1.23K +2,000 New
KFS
24
Kelly Financial Services
Massachusetts
$35 – – –
WS
25
Wedbush Securities
California
– -$56K -89,208 Closed
1
2

NAVB Hedge Fund Activity: Q3 2019 in Review

29 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2019, worth a combined $379K — down 3.3% from $392K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new NAVB positions and 4 closed out — a net gain of 2 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $16.3K. The largest seller was Wedbush Securities, exiting entirely with an estimated $56K sold.

  • 29 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2019, up from 27 in Q2 2019.
  • Funds reported $379K of Navidea Biopharmaceuticals Inc. stock for Q3 2019, down 3.3% quarter-over-quarter.
  • 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2019 and 4 closed out, a net change of +2 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2019 was Vanguard Group, an estimated $16.3K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q3 2019 was Wedbush Securities, an estimated $56K sold.

Based on aggregated 13F filings for Q3 2019.